Abbott Cardiac Catheter Recall Issued Over Embolism Risks

FDA has categorized the action as a Class I Medical Device Recall, after dozens of reports involving problems with Abbott cardiac catheters leaking air inside a patient’s bloodstream, resulting in a risk of serious injury or death

Federal health officials have announced a recall of nearly 700 Abbott cardiac catheters, following at least 26 of reports involving the devices leaking air bubbles into the bloodstream during medical procedures, which increases the risk of an air embolism event and may lead to life-threatening health consequences.

The Abbott catheter recall was given a Class I designation by the U.S. Food and Drug Administration (FDA) on July 26, warning health care professionals that continued use of the devices have a high probability of resulting in serious injury or death.

The cardiac delivery sheaths are steerable catheters inserted through a patient’s skin, designed to work in conjunction with Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder implant, and provides a passageway for permanent heart implants to be inserted into the heart chambers during cardiac procedures.

According the recall notice, the catheter’s hemostasis valve, which was designed to minimize blood loss but were not intended to prevent air ingress, can leak air  bubbles into the patient’s bloodstream during medical procedures, which can travel to the heart and cause an air embolism.

Officials warn that the introduction of air bubbles within the bloodstream can result in severe injuries, including sudden disruption of blood flow to the heart, changes to the heartbeat, low blood pressure, and insufficient blood oxygen levels. In addition, officials indicate an air embolism can also lead to potentially life-threatening consequences, including stroke or death.

Abbott Cardiac Catheter Recall

The recall affects approximately 672 Abbott Amplatzer Steerable Delivery Sheaths, including product model ASDS-14F-075, which were distributed from October 4, 2022 until February 22, 2023.

To date, the medical device manufacturer has received at least 26 complaints in relation to the defective catheters. While no deaths have been reported, Abbott has become aware of at least 16 incidents that resulted in injuries due to the air leaking catheters.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Abbott has instructed medical professionals to stop using the catheters immediately, and use the fixed TorqVue 45°x45° delivery system to perform future Amplatzer Amulet Left Atrial Appendage Occluder cardiac implant procedures.

For more information on the recall, customers are encouraged to contact their local Abbott customer service representative, or they may also contact Abbott’s customer support by phone at 1-800-544-1664, and choose the second option to speak to a representative.

The FDA is also calling on consumers to report any adverse side effects, reactions, or quality defects experienced while using the devices to the MedWatch: The FDA Safety Information and Adverse Event Reporting Program using the online reporting form.

Image Credit: Jonathan Weiss / Shutterstock.com

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted yesterday)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted 2 days ago)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.